Showing 1 - 12 results of 12 for search 'Deborah L. White', query time: 0.04s Refine Results
  1. 1
    Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression

    Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression by Elyse C. Page, Elyse C. Page, Elyse C. Page, Susan L. Heatley, Susan L. Heatley, Jacqueline Rehn, Jacqueline Rehn, Paul Q. Thomas, Paul Q. Thomas, David T. Yeung, David T. Yeung, David T. Yeung, David T. Yeung, David T. Yeung, Deborah L. White, Deborah L. White, Deborah L. White, Deborah L. White, Deborah L. White

    Published 2023-07-01
    Get full text
    Article
  2. 2
    Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis

    Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis by Susan L. Heatley, Susan L. Heatley, Susan L. Heatley, Elyse C. Page, Elyse C. Page, Laura N. Eadie, Laura N. Eadie, Barbara J. McClure, Barbara J. McClure, Jacqueline Rehn, Jacqueline Rehn, David T. Yeung, David T. Yeung, David T. Yeung, David T. Yeung, Michael Osborn, Michael Osborn, Michael Osborn, Michael Osborn, Tamas Revesz, Tamas Revesz, Tamas Revesz, Maria Kirby, Maria Kirby, Deborah L. White, Deborah L. White, Deborah L. White, Deborah L. White, Deborah L. White, Deborah L. White

    Published 2022-04-01
    Get full text
    Article
  3. 3
    Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

    Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells by Devendra K. Hiwase, Verity A. Saunders, Eva Nievergall, Douglas D. Ross, Deborah L. White, Timothy P. Hughes

    Published 2013-06-01
    Get full text
    Article
  4. 4
    The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism

    The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism by Benjamin C. S. Leow, Chung H. Kok, David T. Yeung, Timothy P. Hughes, Deborah L. White, Laura N. Eadie

    Published 2023-08-01
    Get full text
    Article
  5. 5
    OCT-1 function varies with cell lineage but is not influenced by BCR-ABL

    OCT-1 function varies with cell lineage but is not influenced by BCR-ABL by Jane R. Engler, Andrew C.W. Zannettino, Charles G. Bailey, John E.J. Rasko, Timothy P. Hughes, Deborah L. White

    Published 2011-02-01
    Get full text
    Article
  6. 6
    Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

    Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia by Charlotte E. J. Downes, Barbara J. McClure, John B. Bruning, Elyse Page, James Breen, Jacqueline Rehn, David T. Yeung, Deborah L. White

    Published 2021-08-01
    Get full text
    Article
  7. 7
    Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

    Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells by Jueqiong Wang, Liu Lu, Chung H. Kok, Verity A. Saunders, Jarrad M. Goyne, Phuong Dang, Tamara M. Leclercq, Timothy P. Hughes, Deborah L. White

    Published 2017-05-01
    Get full text
    Article
  8. 8
    RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).

    RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL). by Jacqueline Rehn, Chelsea Mayoh, Susan L Heatley, Barbara J McClure, Laura N Eadie, Caitlin Schutz, David T Yeung, Mark J Cowley, James Breen, Deborah L White

    Published 2022-10-01
    Get full text
    Article
  9. 9
    BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

    BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia by Ilaria S. Pagani, Phuong Dang, Ivar O. Kommers, Jarrad M. Goyne, Mario Nicola, Verity A. Saunders, Jodi Braley, Deborah L. White, David T. Yeung, Susan Branford, Timothy P. Hughes, David M. Ross

    Published 2018-12-01
    Get full text
    Article
  10. 10
    Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

    Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized... by Deborah L. White, Jerald Radich, Simona Soverini, Verity A Saunders, Amity K. Frede, Phuong Dang, Daniela Cilloni, Peter Lin, Lidia Mongay, Richard Woodman, Paul Manley, Cassandra Slader, Dong Wook Kim, Fabrizio Pane, Giovanni Martinelli, Giuseppe Saglio, Timothy P. Hughes

    Published 2012-06-01
    Get full text
    Article
  11. 11
    Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

    Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy by Sabrina Angelini, Simona Soverini, Gloria Ravegnini, Matt Barnett, Eleonora Turrini, Mark Thornquist, Fabrizio Pane, Timothy P. Hughes, Deborah L. White, Jerald Radich, Dong Wook Kim, Giuseppe Saglio, Daniela Cilloni, Ilaria Iacobucci, Giovanni Perini, Richard Woodman, Giorgio Cantelli-Forti, Michele Baccarani, Patrizia Hrelia, Giovanni Martinelli

    Published 2013-02-01
    Get full text
    Article
  12. 12
    High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

    High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment by Susan L. Heatley, Teresa Sadras, Chung H. Kok, Eva Nievergall, Kelly Quek, Phuong Dang, Barbara McClure, Nicola Venn, Sarah Moore, Jeffrey Suttle, Tamara Law, Anthea Ng, Walter Muskovic, Murray D. Norris, Tamas Revesz, Michael Osborn, Andrew S. Moore, Ram Suppiah, Chris Fraser, Frank Alvaro, Timothy P. Hughes, Charles G. Mullighan, Glenn M. Marshall, Luciano Dalla Pozza, David T. Yeung, Rosemary Sutton, Deborah L. White

    Published 2017-12-01
    Get full text
    Article

Search Tools: